Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
Juvenile primary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the
fingers and sometimes can affect the toes, nose, or ears. When children with primary
Raynaud's Phenomenon are exposed to chilly or cold conditions from weather, cold
temperatures, or even holding cold items from the refrigerator, their fingers may become
cold, numb, hurt, and/or turn purple or white. Children with primary Raynaud's Phenomenon
have no underlying systemic disease. The cause for their symptoms is unknown. The
investigational drug, Pletal(cilostazol), which has been approved for other conditions,
inhibits the ability of one type of blood cell, platelets, to form blood clots, and also
widens narrowed blood vessels. It has been used in a variety of other conditions in which
blood flow is decreased. This study will test the safety and effectiveness Pletal(cilostazol)
to lessen the severity of the symptoms and decrease the number of primary Raynaud's episodes
in juvenile patients.